Kymera Therapeutics
KYMR
136 hedge funds and large institutions have $1.55B invested in Kymera Therapeutics in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 36 increasing their positions, 53 reducing their positions, and 18 closing their positions.
354% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $433K
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
94% more capital invested
Capital invested by funds: $797M → $1.55B (+$753M)
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
12% more funds holding
Funds holding: 121 → 136 (+15)
6.24% more ownership
Funds ownership: 103.5% → 109.74% (+6.2%)
32% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$22.3M |
| 2 |
AG
Artal Group
Luxembourg
|
+$13M |
| 3 |
Morgan Stanley
New York
|
+$9.71M |
| 4 |
Goldman Sachs
New York
|
+$8.4M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$7.96M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.01M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$5.63M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$3.79M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.59M |
KYMR Hedge Fund Activity: Q4 2023 in Review
136 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2023, worth a combined $1.55B — up 94% from $797M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new KYMR positions and 18 closed out — a net gain of 15 holders — while 36 added to existing stakes and 53 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $22.3M. The largest seller was Wasatch Advisors, exiting entirely with an estimated $7.96M sold.
- 136 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2023, up from 121 in Q3 2023.
- Funds reported $1.55B of Kymera Therapeutics stock for Q4 2023, up 94% quarter-over-quarter.
- 33 funds opened new Kymera Therapeutics positions in Q4 2023 and 18 closed out, a net change of +15 holders.
- The largest Kymera Therapeutics buyer in Q4 2023 was Baker Bros. Advisors, an estimated $22.3M added.
- The largest Kymera Therapeutics seller in Q4 2023 was Wasatch Advisors, an estimated $7.96M sold.
Based on aggregated 13F filings for Q4 2023.